Ignite Creation Date:
2025-12-25 @ 1:04 AM
Ignite Modification Date:
2026-02-25 @ 9:40 PM
Study NCT ID:
NCT02953093
Status:
TERMINATED
Last Update Posted:
2025-06-24
First Post:
2016-09-09
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Study of Acarbose in Longevity
Sponsor:
Montefiore Medical Center
Organization:
Study Overview
Official Title:
Study of Changes in Muscle and Fat Gene Transcription With Acarbose Treatment: a Crossover Study
Status:
TERMINATED
Status Verified Date:
2025-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Upon review it was determined that the study terminated early due to lack of funding. Study never reached enrollment target and was administratively closed out by the Albert Einstein College of Medicine IRB.
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
SAIL
Brief Summary:
The investigators are studying the effects of acarbose on muscle and adipose gene transcription in older adults.
Detailed Description:
Acarbose, an FDA approved drug for the treatment of type 2 diabetes, has known effects on glucose metabolism. Evidence from mice indicates that acarbose may prolong lifespan. In humans, acarbose improves inflammatory markers and reduces cardiovascular events. Consequently, acarbose is of interest in clinical translational aging research since it may influence fundamental processes that contribute to age-related diseases. The study described herein is an exploratory study to examine the effect of acarbose treatment on the biology of aging in humans. Specifically, the investigators plan to study whether treatment with a 10 week course of acarbose will alter the gene expression profile in adipose tissue and muscle in older adults in pathways that are known to be affected by human aging, in a placebo-controlled crossover study.
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: